500680 Stock Overview Engages in manufacturing, marketing, trading, and export of pharmaceutical products in India and internationally. More details
Rewards Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
Pfizer Limited Competitors Price History & Performance
Summary of share price highs, lows and changes for Pfizer Historical stock prices Current Share Price ₹4,536.05 52 Week High ₹6,452.85 52 Week Low ₹4,050.10 Beta 0.23 1 Month Change -14.40% 3 Month Change -12.04% 1 Year Change -2.43% 3 Year Change 1.43% 5 Year Change 12.17% Change since IPO 226.33%
Recent News & Updates
Pfizer Limited Announces Resignation of Amit Sharma as Director Jan 31 FeganScott Announces Class-Action Lawsuit Against Pfizer and Viatris Jan 18
Pfizer Limited Appoints Mr. Chetan Solse as India Legal Lead, Effective November 18, 2024 Nov 15
Pfizer Limited Announces Board and Committee Changes Nov 11
Pfizer Limited Announces Executive Appointments, Effective November 7, 2024 Nov 05
Second quarter 2025 earnings released: EPS: ₹34.61 (vs ₹32.56 in 2Q 2024) Oct 29 See more updates
Pfizer Limited Announces Resignation of Amit Sharma as Director Jan 31 FeganScott Announces Class-Action Lawsuit Against Pfizer and Viatris Jan 18
Pfizer Limited Appoints Mr. Chetan Solse as India Legal Lead, Effective November 18, 2024 Nov 15
Pfizer Limited Announces Board and Committee Changes Nov 11
Pfizer Limited Announces Executive Appointments, Effective November 7, 2024 Nov 05
Second quarter 2025 earnings released: EPS: ₹34.61 (vs ₹32.56 in 2Q 2024) Oct 29
High number of new directors Sep 02
Pfizer Limited Approves to Declare A Dividend for the Financial Year Ended March 31, 2024 Aug 30
Dividend of ₹35.00 announced Aug 09
Pfizer Limited, Annual General Meeting, Aug 28, 2024 Aug 08 Pfizer Limited, Annual General Meeting, Aug 28, 2024
Price target increased by 10% to ₹5,477 Aug 02
First quarter 2025 earnings released: EPS: ₹32.94 (vs ₹20.44 in 1Q 2024) Jul 30
Pfizer Limited to Report Q1, 2025 Results on Jul 29, 2024 Jul 22
Full year 2024 earnings released: EPS: ₹121 (vs ₹136 in FY 2023) May 18
Pfizer Limited Recommends Dividend for the Financial Year Ended March 31, 2024, Payable on or Before September 6, 2024 May 18
Pfizer Limited to Report Q4, 2024 Results on May 17, 2024 May 08 Pfizer Limited Appoints Amit Agarwal as Chief Financial Officer
China's National Medical Products Administration Accepts Astellas and Pfizer's Supplemental Biologics License Application for Enfortumab Vedotin with Keytruda (Pembrolizumab) for First-Line Treatment of Advanced Bladder Cancer Mar 28
Third quarter 2024 earnings released: EPS: ₹28.42 (vs ₹32.93 in 3Q 2023) Feb 11
Pfizer Limited Informs Satyen Amin, Lead - Market Access Tenders His Resignation from Employment, with Effect from March 31, 2024 Feb 09
Pfizer Limited to Report Q3, 2024 Results on Feb 09, 2024 Feb 01
Pfizer Limited Appoints Ms. Aditi Mehta as Category Lead, Vaccines Effective December 1, 2023 Nov 17
Pfizer Limited Announces Resignation of Mr. Milind Patil as Director with Effect from Close of Business on November 13, 2023 Nov 15
Pfizer Limited Announces Resignation of Samir Kazi as Director from the Board of Directors Oct 29
Second quarter 2024 earnings released: EPS: ₹32.56 (vs ₹67.99 in 2Q 2023) Oct 29
Pfizer Limited to Report Q2, 2024 Results on Oct 28, 2023 Oct 19
Pfizer Limited Appoints Chaitanya Nadkarni as India Digital Client Partner Lead Sep 07
Pfizer Limited Approves A Final Dividend for the Financial Year Ended March 31, 2023 Aug 22
New major risk - Revenue and earnings growth Aug 22
Pfizer Limited Announces Change in Management, Effective September 1, 2023 Aug 18
Pfizer Limited to Report Q1, 2024 Results on Aug 11, 2023 Aug 05
Upcoming dividend of ₹40.00 per share at 0.9% yield Aug 04
Full year 2023 earnings released: EPS: ₹136 (vs ₹134 in FY 2022) Jul 29
Pfizer Limited, Annual General Meeting, Aug 18, 2023 Jul 29
Pfizer Limited Proposes Final Dividend for the Financial Year Ended March 31, 2023 Jul 28
Pfizer Limited Initiates Voluntary Recall Of Magnex 1gm, 2gm, Magnex Forte 1.5gm, 3gm, Zosyn 4.5gm and Magnamycin 250mg, 1gm, 2gm Injections May 19
Price target decreased by 7.9% to ₹4,595 May 17 Pfizer Limited Recommends A Final Dividend for the Financial Year Ended March 31, 2023, Payable on or Before September 16, 2023
Full year 2023 earnings released: EPS: ₹136 (vs ₹134 in FY 2022) May 16
Pfizer Limited to Report Fiscal Year 2023 Results on May 15, 2023 May 06
Third quarter 2023 earnings released: EPS: ₹32.93 (vs ₹31.46 in 3Q 2022) Feb 12 Pfizer India Appoints Meenakshi Nevatia as CEO
Second quarter 2023 earnings released: EPS: ₹67.99 (vs ₹31.25 in 2Q 2022) Nov 16
Insufficient new directors Nov 16
Second quarter 2023 earnings released: EPS: ₹67.99 (vs ₹31.25 in 2Q 2022) Nov 13
Upcoming dividend of ₹30.00 per share Sep 12
Pfizer Limited Announces Interim (Special) Dividend for the Financial Year Ending March 31, 2023, Payable on or Before September 30, 2022 Sep 07
Pfizer Limited Approves Declaration of Dividend for the Financial Year Ended March 31, 2022 Aug 28
Upcoming dividend of ₹35.00 per share Aug 11
Pfizer Announces Resignation of S. Sridhar as Managing Director Aug 10
Pfizer Limited Proposes Dividend for the Financial Year Ended March 31, 2022 Aug 06
First quarter 2023 earnings released Aug 06 Pfizer Limited Proposes Dividend for the Financial Year Ended March 31, 2022
Mylan Pharmaceuticals Private Limited completed the acquisition of off-patent branded and generic established medicines business from Pfizer Limited (BSE:500680). Aug 02
Pfizer Limited to Report Q1, 2023 Results on Aug 05, 2022 Jul 28
Now 20% undervalued after recent price drop Jul 12
Price target decreased to ₹5,201 Jun 14
Now 21% undervalued after recent price drop Jun 08
Full year 2022 earnings released: EPS: ₹134 (vs ₹109 in FY 2021) May 22
Pfizer Limited Recommends Dividend for the Financial Year Ended March 31, 2022, Payable on or before September 23, 2022 May 21
Price target decreased to ₹5,654 Apr 27
Insufficient new directors Apr 27
Insufficient new directors Apr 02
Pfizer and FDA Dropped Data Bombshell on Covid Vaccine Consumers Mar 06
Price target decreased to ₹5,749 Mar 02
Third quarter 2022 earnings: Revenues and EPS in line with analyst expectations Feb 05
Pfizer Limited Announces Board Changes Feb 04
Pfizer Limited Announces Resignation of R. A. Shah as an Independent Director Feb 03
Second quarter 2022 earnings released: EPS ₹31.25 (vs ₹28.71 in 2Q 2021) Nov 04
Upcoming dividend of ₹35.00 per share Aug 04
Price target increased to ₹6,099 Aug 03
Price target increased to ₹5,945 Aug 01
First quarter 2022 earnings released: EPS ₹43.69 (vs ₹27.20 in 1Q 2021) Jul 29
Full year 2021 earnings released: EPS ₹109 (vs ₹111 in FY 2020) May 28 Pfizer Limited Recommends Normal Dividend for the Year Ended March 31, 2021, Payable on or Before September 15, 2021
GlobalSpace Technologies Limited Announces Strategic Partnership with Pfizer Feb 18
New 90-day low: ₹4,464 Feb 09
Third quarter 2021 earnings released: EPS ₹30.87 (vs ₹30.40 in 3Q 2020) Feb 06
New 90-day low: ₹4,862 Jan 21
New 90-day high: ₹5,338 Dec 07
New 90-day high: ₹5,203 Nov 11
Second quarter 2021 earnings released: EPS ₹28.71 Nov 03
New 90-day high: ₹5,062 Oct 22 Pfizer Limited to Report Q3, 2021 Results on Feb 14, 2021 Shareholder Returns 500680 IN Pharmaceuticals IN Market 7D -3.7% -4.0% -1.8% 1Y -2.4% 20.3% 6.2%
See full shareholder returns
Return vs Market: 500680 underperformed the Indian Market which returned 6.2% over the past year.
Price Volatility Is 500680's price volatile compared to industry and market? 500680 volatility 500680 Average Weekly Movement 4.8% Pharmaceuticals Industry Average Movement 6.0% Market Average Movement 6.3% 10% most volatile stocks in IN Market 9.1% 10% least volatile stocks in IN Market 4.3%
Stable Share Price: 500680 has not had significant price volatility in the past 3 months compared to the Indian market.
Volatility Over Time: 500680's weekly volatility (5%) has been stable over the past year.
About the Company Pfizer Limited engages in manufacturing, marketing, trading, and export of pharmaceutical products in India and internationally. It offers its products in various therapeutic areas, including neuro/CNS, hormones, cardiovascular, haemophilia, anti-infectives, gynecology, pain/analgesics, orthopedic, oncology, urology, anti-parasitic, gastro intestinal, vaccines, and respiratory, as well as vitamins, minerals, and nutrients. The company also offers internal medicine and anti-infectives services to hospitals and nursing homes.
Show more Pfizer Limited Fundamentals Summary How do Pfizer's earnings and revenue compare to its market cap? 500680 fundamental statistics Market cap ₹207.61b Earnings (TTM ) ₹6.18b Revenue (TTM ) ₹22.38b
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) 500680 income statement (TTM ) Revenue ₹22.38b Cost of Revenue ₹7.89b Gross Profit ₹14.49b Other Expenses ₹8.31b Earnings ₹6.18b
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
May 29, 2025
Earnings per share (EPS) 135.07 Gross Margin 64.75% Net Profit Margin 27.61% Debt/Equity Ratio 0.07%
How did 500680 perform over the long term?
See historical performance and comparison Dividends
0.8% Current Dividend Yield
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2025/01/31 20:13 End of Day Share Price 2025/01/31 00:00 Earnings 2024/09/30 Annual Earnings 2024/03/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Pfizer Limited is covered by 13 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Sriraam Rathi Anand Rathi Shares and Stock Brokers Limited null null Anand Rathi Shares and Stock Brokers Limited Rohit Bhat Batlivala & Karani Securities India Pvt. Ltd.
Show 10 more analysts 
